Last updated: 2026-09-09 04:53:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Inovio Pharmaceuticals, Inc. (INO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.41, with a market capitalization of $147.86M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.56 to $2.98. This page covers its latest market performance, valuation, price trends and company information.
$147.86M | |
$1.43 | |
$405.48 | |
$0.56 | |
$1.43 | |
3.42M | |
3.45M | |
-- | |
$2.98 | |
$0.56 | |
-- | |
-- |
Inovio Pharmaceuticals, Inc. (INO) last closed at $1.43 as of 2026-09-08 23:56:00, unchanged from the previous close of $1.43.
During the latest regular trading session, INO traded between $0.56 and $405.48, with a volume of 3.42M shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Inovio Pharmaceuticals, Inc. (INO) moved from $1.26 to $1.41, representing a gain of 12.22% ($0.15).
The stock traded between $1.22 and $1.46 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 3.40 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 35.2%
INO is currently trading at $1.41, placing it 35.2% of the way from its 52-week low of $0.56 to its 52-week high of $2.98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 112 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Inovio Pharmaceuticals, Inc. (INO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.